Experimental infection and protection against ... - TI Pharma

114 Chapter 5
References
1. McCall MB, Netea MG, Hermsen CC et al. Plasmodium falciparum infection
causes proinflammatory priming of human TLR responses. J Immunol 2007;
179:162-171.
2. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge
infections can accelerate clinical malaria vaccine development. Nat Rev
Immunol 2011; 11:57-64.
3. Andrews L, Andersen RF, Webster D et al. Quantitative real-time polymerase
chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials.
Am J Trop Med Hyg 2005; 73:191-198.
4. Felger I, Genton B, Smith T, Tanner M, Beck HP. Molecular monitoring in
malaria vaccine trials. Trends Parasitol 2003; 19:60-63.
5. Hermsen CC, Telgt DS, Linders EH et al. Detection of Plasmodium falciparum
malaria parasites in vivo by real-time quantitative PCR. Mol Biochem Parasitol
2001; 118:247-251.
6. Epstein JE, Rao S, Williams F et al. Safety and clinical outcome of experimental
challenge of human volunteers with Plasmodium falciparum-infected
mosquitoes: an update. J Infect Dis 2007; 196:145-154.
7. Verhage DF, Telgt DS, Bousema JT et al. Clinical outcome of experimental
human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth J
Med 2005; 63:52-58.
8. McCall MB, Beynon AJ, Mylanus EA, van d, V, Sauerwein RW. No hearing loss
associated with the use of artemether-lumefantrine to treat experimental
human malaria. Trans R Soc Trop Med Hyg 2006; 100:1098-1104.
9. Roestenberg M, McCall M, Hopman J et al. Protection against a malaria
challenge by sporozoite inoculation. N Engl J Med 2009; 361:468-477.
10. Roestenberg M, Teirlinck AC, McCall MB et al. Long-term protection against
malaria after experimental sporozoite inoculation: an open-label follow-up
study. Lancet 2011.
11. Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal
cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987-
1003.
12. Thompson FM, Porter DW, Okitsu SL et al. Evidence of blood stage efficacy with
a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One 2008; 3:e1493.
13. Dunachie SJ, Walther M, Epstein JE et al. A DNA prime-modified vaccinia virus
ankara boost vaccine encoding thrombospondin-related adhesion protein but
not circumsporozoite protein partially protects healthy malaria-naive adults
against Plasmodium falciparum sporozoite challenge. Infect Immun 2006;
74:5933-5942.
14. Walther M, Thompson FM, Dunachie S et al. Safety, immunogenicity, and
efficacy of prime-boost immunization with recombinant poxvirus FP9 and
modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum
circumsporozoite protein. Infect Immun 2006; 74:2706-2716.